GGrantIndex
← Leaderboards

Oliver Michael Colvin

Duke University

$5,510,946
Attributed
$5,510,946
Total exposure
9
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $754.1K · FY200510
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10

Funding mix

By agency

NIH$16,858,074 · 10

By mechanism

P30$12,096,928 · 2
R01$2,510,372 · 1
U01$1,724,741 · 2
P01$522,927 · 1
P41$3,106 · 4

Top collaborators

No co-investigators on record.

Most similar at Duke University

Same institution · by research overlap

Others in their field

Top investigators on “Neoplasm /Cancer Pharmacology

Research focus

Neoplasm /Cancer PharmacologyPharmacokineticsBiomedical FacilityCyclophosphamideNeoplasm /CancerCytochrome P450AlkylationIfosfamideDrug ResistanceTissue /Cell CultureOxidationCrosslinkEnzyme ActivityNeoplasm /Cancer ChemotherapyAdductDeoxyguanosineGlutathione TransferaseGlutathioneHealth Science Research SupportMethylationGas Chromatography Mass SpectrometryDeuteriumAcroleinAziridines

Grant awards (38)

EDUCATION - 2008 UC MERCED SUMMER COMPUTATIONAL BIOLOGY PROGRAM$1,091
P41 · FY2010 · RR · contact PI
EDUCATION - 2008 UC MERCED SUMMER COMPUTATIONAL BIOLOGY PROGRAM$771
P41 · FY2009 · RR · contact PI
MOLECULAR DYNAMICS SIMULATIONS OF NATIVELY UNFOLDED PROTEINS$771
P41 · FY2009 · RR · contact PI
Pharmacology of Cyclophosphamide and Other Alkylators$287,853
R01 · FY2008 · CA · contact PI
MOLECULAR DYNAMICS SIMULATIONS OF NATIVELY UNFOLDED PROTEINS$473
P41 · FY2008 · RR · contact PI
Pharmacology of Cyclophosphamide and Other Alkylators$286,398
R01 · FY2007 · CA · contact PI
Biomarker Studies for Novel Anti-Cancer Agents$62,170
U01 · FY2007 · CA · contact PI
Pharmacology of Cyclophosphamide and Other Alkylators$286,303
R01 · FY2006 · CA · contact PI
Biomarker Studies for Novel Anti-Cancer Agents$109,456
U01 · FY2006 · CA · contact PI
Biomarker Studies for Novel Anti-Cancer Agents$50,888
U01 · FY2006 · CA · contact PI
Biomarker Studies for Novel Anti-Cancer Agents$405,261
U01 · FY2005 · CA
Pharmacology of Cyclophosphamide and Other Alkylators$299,254
R01 · FY2005 · CA
Biomarker Studies for Novel Anti-Cancer Agents$49,585
U01 · FY2005 · CA
Biomarker Studies for Novel Anti-Cancer Agents$370,148
U01 · FY2004 · CA
PHARMACOLOGY OF CYCLOPHOSPHAMIDE AND OTHER ALKYLATORS$278,203
R01 · FY2004 · CA
Biomarker Studies for Novel Anti-Cancer Agents$48,321
U01 · FY2004 · CA
Biomarker Studies for Novel Anti-Cancer Agents$294,991
U01 · FY2003 · CA
PHARMACOLOGY OF CYCLOPHOSPHAMIDE AND OTHER ALKYLATORS$270,164
R01 · FY2003 · CA
PHARMACOLOGY OF CYCLOPHOSPHAMIDE AND OTHER ALKYLATORS$262,296
R01 · FY2002 · CA
CORE--DEVELOPMENTAL FUNDS$187,450
P30 · FY2002 · CA
COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT$5,474,056
P30 · FY2001 · CA
PHARMACOLOGY$228,401
P01 · FY2001 · CA
PHARMACOLOGY OF CYCLOPHOSPHAMIDE AND OTHER ALKYLATORS$189,986
R01 · FY2001 · CA
CORE--DEVELOPMENTAL FUNDS$187,450
P30 · FY2001 · CA
CORE--DEVELOPMENTAL FUNDS$187,450
P30 · FY2001 · CA
CORE--DEVELOPMENTAL FUNDS$187,450
P30 · FY2001 · CA
COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT$174,652
P30 · FY2001 · CA
COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT$154,000
P30 · FY2001 · CA
PHARMACOLOGY OF CYCLOPHOSPHAMIDE AND OTHER ALKYLATORS$18,462
R01 · FY2001 · CA
CORE--DEVELOPMENTAL FUNDS$0
P30 · FY2001 · CA
COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT$5,390,420
P30 · FY2000 · CA
METHODS TO IMPROVE CAMPTOTHECAN BASED CHEMOTHERAPY$333,921
U01 · FY2000 · CA
PHARMACOLOGY OF CYCLOPHOSPHAMIDE AND OTHER ALKYLATORS$304,178
R01 · FY2000 · CA
PHARMACOLOGY$294,526
P01 · FY2000 · CA
COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT$154,000
P30 · FY2000 · CA
PHARMACOLOGY OF CYCLOPHOSPHAMIDE AND OTHER ALKYLATORS$27,275
R01 · FY2000 · CA
CORE--DEVELOPMENTAL FUNDS$0
P30 · FY2000 · CA
CORE--DEVELOPMENTAL FUNDS$0
P30 · FY2000 · CA